Skip to Main Content
Try STAT+ TODAY
Trending:
Health
Biotech
STAT+
First Opinion
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Health
STAT+

STAT+ Conversation: Can tech improve health care’s value proposition?

  • Erin Brodwin

By Erin Brodwin Oct. 12, 2021

Reprints

Editor’s note: A recording of the conversation is embedded below.

Every week, STAT+ subscribers get access to exclusive conversations with biotech, pharma, and health tech leaders. This week, STAT health tech correspondent Erin Brodwin will be joined by Glen Tullman, executive chairman and CEO of Transcarent. Coming off the success of Livongo, Tullman will discuss his new ideas for revamping employer-based health, and of course be taking your questions live.

advertisement

Featured Speakers:

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Erin Brodwin

Erin Brodwin

Health Tech Correspondent, San Francisco

Erin was a California-based health tech reporter and the co-author of the STAT Health Tech newsletter.

linkedin.com/in/erinbrodwin/

Tags

Create a display name to comment

This name will appear with your comment

There was an error saving your display name. Please check and try again.

Insurance alone didn’t guarantee adherence to Ozempic, study finds
Insurance alone didn’t guarantee adherence to Ozempic, study finds
Tired of ‘dead end’ approach, herpes patients mobilize to…
Tired of ‘dead end’ approach, herpes patients mobilize to demand government action
Revenge of the gaslit patients: Now, as scientists, they’re…
Revenge of the gaslit patients: Now, as scientists, they’re tackling Ehlers-Danlos syndromes
Insurance alone didn’t guarantee adherence to Ozempic, study finds
Insurance alone didn’t guarantee adherence to Ozempic, study finds
U.S. births in 2022 didn’t return to pre-pandemic levels
U.S. births in 2022 didn’t return to pre-pandemic levels
FDA approves Pfizer’s RSV vaccine for older adults
FDA approves Pfizer’s RSV vaccine for older adults

Recommended Stories